BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NYSE MKT:TXMD) (the “Company”) today announced the launch of an underwritten public offering of $40 million of shares of its common stock. All of the shares in the offering are to be sold by the Company. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. In addition, the Company has granted the underwriters an option for a period of 30 days to purchase, at the public offering price less the underwriting discount, up to an additional $6 million of shares of its common stock.
Goldman, Sachs & Co. is acting as sole book-running manager for the offering and Noble Capital Markets is acting as co-manager for the offering.
The Company has filed a shelf registration statement on Form S-3, including a prospectus supplement and accompanying prospectus, with the Securities and Exchange Commission, or SEC, relating to the public offering of the shares of common stock described above. Before buying any shares of the Company’s common stock in the offering, you should carefully read the prospectus supplement and the accompanying prospectus, together with the information incorporated therein. These documents contain important information that you should consider when making your investment decision. The Company’s SEC filings are available to the public from the SEC’s website at www.sec.gov. Alternatively, you may request the prospectus supplement and accompanying prospectus by contacting Goldman, Sachs & Co., Prospectus Department, 200 West Street, New York, NY 10282, by calling (866) 471-2526, or by emailing email@example.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About TherapeuticsMD, Inc.
TherapeuticsMD, Inc. is a women’s healthcare company focused on developing and commercializing products targeted exclusively for women. TherapeuticsMD is developing advanced hormone therapy pharmaceutical products based on novel technologies that enable delivery of bioidentical hormones through a variety of dosage forms and administration routes. The company also manufactures and distributes branded and generic prescription prenatal vitamins, as well as over-the-counter vitamins and cosmetics, under the vitaMedMD® and BocaGreenMD® brands.
vitaMedMD®, BocaGreenMD® and TherapeuticsMD® are registered trademarks of the Company.
Except for the historical information contained herein, the matters set forth in this press release, including statements regarding the Company’s expectations with respect to the proposed offering, are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with market conditions, the satisfaction of customary closing conditions related to the offering, risks and uncertainties associated with Company’s business and finances in general, and other risks detailed in the Company’s annual report on Form 10-K filed with the SEC on March 5, 2014 and other filings with the SEC. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.